Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models

PURPOSE: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. Prexasertib (LY2606368) is a CHK1 small molecule inhibitor under clinical evaluation in multiple adult and pedi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lowery, Caitlin D., Dowless, Michele, Renschler, Matthew, Blosser, Wayne, VanWye, Alle B., Stephens, Jennifer R., Iversen, Philip W., Lin, Aimee Bence, Beckmann, Richard P., Krytska, Kateryna, Cole, Kristina A., Maris, John M., Hawkins, Douglas S., Rubin, Brian P., Kurmasheva, Raushan T., Houghton, Peter J., Gorlick, Richard, Kolb, E. Anders, Kang, Min H., Reynolds, C. Patrick, Erickson, Stephen W., Teicher, Beverly A., Smith, Malcolm A., Stancato, Louis F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445779/
https://ncbi.nlm.nih.gov/pubmed/30563935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2728
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados